Adicet Bio (LTS:0HX7) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0HX7 Adicet Bio Inc LTS:0HX7
31 GF Score
Price $8.66
GF Value $0.44
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Adicet Bio FFO?

FFO (Funds from operations) only applies to REITs.

LTS:0HX7
31GF Score
Adicet Bio Inc LTS:0HX7
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Adicet Bio (LTS:0HX7) Overvalued in 2026?

Based on GuruFocus' analysis, Adicet Bio stock appears to be overvalued. The current stock price of $8.66 is trading 1868.2% above its estimated GF Value™ of $0.44. GuruFocus considers Adicet Bio to be Significantly Overvalued.

Key valuation signals for LTS:0HX7:

  • FFO:
  • GF Value™: $0.44 vs. price of $8.66 (1868.2% above fair value)
  • GF Score™: 31/100 with 2 warning signs

No single metric tells the full story. See the LTS:0HX7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Adicet Bio Business Description

Other Exchanges ACET:USA
Address 131 Dartmouth Street, 3rd Floor, Boston, MA, USA, 02116
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
31GF Score

Get the complete analysis for LTS:0HX7

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.66
Price
$0.44
GF Value